Introduction
In the bone microenvironment, tumour necrosis factor (TNF) has long been established as a stimulator of osteoclasts, hence leading to bone resorption, [1] [2] [3] [4] yet it also induces osteoblasts, the bone-forming cells, to proliferate, which may have longer term influences on bone formation. 5 A disturbance in the finely balanced processes of bone resorption and formation, termed remodelling, results in a disordered state. 6 The effects of TNF during diseases such as rheumatoid arthritis, osteoporosis and arthritis are dramatic, the presence of TNF being linked to the accelerated bone resorption associated with these bone disorders. [7] [8] [9] Levels of TNF in bone also appear to be elevated in bone infections. At the time of surgical intervention, TNF is elevated in bone tissues and transiently elevated in the serum of acute (but not chronic) post-traumatic osteomyelitis patients. 10 This may be a direct result of infection as several bacterial components can cause bone resorption. 6 Many of these components are likely to be released during antibiotic-induced lysis 11 and are capable of inducing the formation of cytokines, including TNF. 12 Some surface-associated proteins of Staphylococcus aureus are capable of inducing cells within bone to release several bone-resorbing factors including TNF, although these proteins can also act independently of TNF to induce osteolysis. 13 The combination of azithromycin and rifampicin was previously shown to be a particularly effective treatment regime for experimental acute S. aureus osteomyelitis. 14 Chronic osteomyelitis is generally more difficult to treat than acute osteomyelitis [15] [16] [17] and part of the purpose of this study was to evaluate the combination of azithromycin and rifampicin in a model of chronic osteomyelitis. In this study, we have also investigated the effect of antibacterial therapy on bone TNF activity and TNF mRNA levels and examined the damage caused within bone during experimentally induced chronic osteomyelitis.
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Effect of combination therapy of rifampicin and azithromycin on TNF levels during a rat model of chronic osteomyelitis 
Infection model and antibacterial treatment
The infection protocol was approved by the Ethical Committee of the Kantonales Veterinaramt of Basel Stadt and was based on previous descriptions of this model. 14, 18 Briefly, the left tibial bones were surgically exposed, a 1 mm hole was drilled in the medullary cavity into which 50 L of sodium morrhuate (5% w/v) and a 50 L suspension of S. aureus 1098 strain (log 9 cfu) were injected. Uninfected animals received sterile saline instead of bacterial inocula. Beginning 56 days after infection, animals were randomized and treated for 21 days either with saline or with the antibiotics azithromycin (Pfizer, Zurich, Switzerland) at 50 mg/kg of body weight po and rifampicin (Ciba, Basle, Switzerland) at 20 mg/kg sc, once daily. Groups of eight animals were killed at day 56 (before treatment), and days 81, 84 and 98 (4 days, 1 week and 3 weeks after treatment, respectively).
Analyses
The tibia were removed, dissected free of adhering soft tissue and weighed, and five of the eight were subsequently frozen in liquid nitrogen. The five bones were powdered using individual metal ball mills (Retsch, Haan, Germany). The powder was sub-divided for bacteriology, RNA extraction and determination of TNF activity. For determination of bacterial load, 10 mg of bone powder was weighed and resuspended in 1 mL 0.9% (w/v) NaCl and serially diluted and plated on to brain heart infusion agar (Difco, Chemie Brunschweig AG, Basle, Switzerland), and incubated for 24 h at 37°C for determination of cfu. Results were expressed as log 10 cfu/g of bone.
Previous results indicate that in osteomyelitic bones, azithromycin is present at 37 g/g bone and rifampicin at 0.7 g/g bone 4 days after cessation of treatment. 14, 15 Therefore, the carryover of antibiotics would be 1/55 MIC for azithromycin and 1/17 MIC for rifampicin in the lowest dilutions used for cfu determinations.
For the determination of bone TNF activity, 10 mg of bone powder was suspended in 200 L of RPMI 1640 medium containing 10% (v/v) fetal calf serum, 100 units/mL penicillin, 100 mg/L streptomycin and 2 mM Lglutamine (Gibco-BRL, Life Technologies AG, Basle, Switzerland) and incubated for 5 min at room temperature with strong agitation. The supernatant was carefully removed after the suspension had been centrifuged at 10,000g for 5 min, and was used to measure TNF activity using the cytotoxic WEHI 164 bioassay as described previously. 19 For the determination of TNF mRNA abundance in bone, total RNA was extracted from powdered tibia by the acid guanidinium thiocyanate-phenol-chloroform extraction method described elsewhere. 20 Ten micrograms of RNA was electrophoresed in a formaldehyde gel and transferred on to a Hybond N membrane (Amersham) overnight. The filter was hybridized with a randomly primed 32 P-labelled (Boehringer-Mannheim AG, Rotkreuz, Switzerland) rabbit TNF probe 21 which has a 340 bp 5 region of the gene exhibiting over 80% homology to the rat gene, and a 1500 bp fragment probe of rat glyceraldehyde phosphate dehydrogenase (GAPDH); both probes were obtained from Dr G. Bilbe, Ciba-Geigy Limited, Basle, Switzerland. The hybridized filters were exposed on a Phosphor-imager screen for densitometry determination and the TNF mRNA signal corrected for loading errors with the GAPDH housekeeping signal. The TNF mRNA levels were then expressed as fold change over uninfected bones at day 56.
Histological analysis was performed on two bones from each group. The undecalcified bones were embedded in methylmethacrylate and 10 m sections were cut, mounted on gelatin-coated slides and stained using Goldner and haematoxylin/eosin methods. 22 
Statistical analyses
Treatment groups were compared using ANOVA (Fisher PLSD) using a commercially available program (Staview II, Abacus Concepts, Berkeley, CA, USA). Table I presents the mean bone weights, and bone cfu and TNF activity data during experimental chronic S. aureus osteomyelitic infection in rats. The uninfected (but drilled) bones remained sterile, demonstrated an increase in weight consistent with increase in body weight of the animals, and possessed TNF activity at the limit of detection ( 0.01 ng/g bone). Infected, saline-treated animals demonstrated elevated bone weights, TNF activity and bacterial counts. Bacterial load was stable at approximately 6 log cfu/g bone throughout the duration of the experiment. TNF activity was consistently elevated by 200-fold (P 0.05) over uninfected animals and the average bone weights were significantly (P 0.05) heavier in the infected, saline-treated rats.
Results

Effect of antibiotic treatment on bone bacteriology, TNF activity and TNF mRNA levels
Treatment with azithromycin combined with rifampicin resulted in the reduction of bacterial counts to below the limit of detection ( 1.81 log cfu/g bone) in all animals 4 days after cessation of antibiotic therapy (Table I) . However, during later time points the bacterial counts increased again, indicating lack of sterility of the bones and suggesting that the duration of treatment was insufficient. Antibiotic treatment did not affect the TNF activity or the bone weights during the observation period when compared with the corresponding infected, saline-treated animals (Table I ; P 0.05 for all time points).
Elevated bone TNF levels in infected animals were accompanied with increased bone TNF mRNA levels. Two TNF mRNA transcripts (2.4 and 1.6 kb), which were barely detectable in the bones of uninfected rats, were elevated by approximately 20-fold in the bones of infected rats. Antibacterial therapy did not reduce the elevated TNF mRNA levels (Table II) .
Effect of antibiotic treatment on bone histopathology
The Figure reveals the bone histological changes in rats with chronic osteomyelitis. The drilled uninfected bones demonstrated a normal histology 81 days post drilling (Figure, panel a) . A similar histological picture was observed at earlier and later time points (not shown) and was similar to bones from age-matched, unmanipulated animals (not shown), indicating that the trauma associated with the drilling procedure resulted in no long-term changes to the bone. This is in congruence with bone sterility and lack of TNF activity and low TNF mRNA levels within bone. However, there were extensive changes in the infected bones, including fibrous deposition and polymorphonuclear cellular infiltration within the marrow space, extensive bone resorption resulting in frequent observation of sequestra, and new woven bone formation both subperiosteally and in the marrow cavity. Panel b of the Figure demonstrates these histopathological findings at 81 days after infection, and similar profil e s were observed at 56, 84 and 98 days after infection. The marrow space is filled with fibrous tissue and contains a sequestered piece of bone covered by osteoclasts (large arrow). Additionally, extensive new bone formation is observed in this section of untreated bone, with osteoblasts laying down unmineralized bone (osteoid) (small arrow). There was no histopathological difference between the antibiotic-treated and untreated bones throughout the infection. Panel c represents a section of antibiotic treated bone taken at day 81 (at the completion of antibiotic treatment when the bones had very low bacterial loads, but elevated TNF mRNA and TNF activity levels), and shows extensive bone sequestration, with islands of necrotic bone covered by osteoclasts resorbing them (small arrow). In addition, the marrow is replaced by fibrous deposits and is infiltrated with polymorphonuclear cells (large arrow). At other sites within this bone, marked new bone formation was detected (data not shown). Panel d is a section of antibiotic-treated bone taken at day 98. This reveals osteoblasts depositing Rats were infected by direct inoculation with log 7.7 cfu S. aureus 1098 and treatment with saline or azithromycin (Az; 50 mg/kg po) plus rifampicin (Rif; 20 mg/kg sc) for 21 days commencing 56 days after infection. The TNF mRNA transcripts were normalized to a GAPDH housekeeping gene and intensity of the hybridization signals exposed on a Phosphorimager screen for densitometry readings. The resultant figures were expressed as a fold change over the uninfected bones at day 56.
Figure.
Histological profiles (Goldner staining) of bones from uninfected rats and rats with experimental S. aureus osteomyelitis treated with either saline or azithromycin plus rifampicin. Rats were either manipulated (drilled), but uninfected (a, 81 days after infection), or infected by direct inoculation with log 9 cfu S. aureus 1098 and treatment with saline (b, 81 days after infection) or azithromycin (50 mg/kg, po) plus rifampicin (25 mg/kg, sc) for 21 days commencing 56 days after infection (c, 81 days after infection, d, 98 days after infection).
osteoid leading to the accumulation of fine spicules of newly formed bone in the marrow cavity. The newly formed bone is already being resorbed by osteoclasts lining the trabeculae (arrow), demonstrating the high turnover of bone observed in this disease.
Discussion
The dual therapy of azithromycin and rifampicin has previously been shown to be an effective combination in experimental acute S. aureus osteomyelitis. 14 In this study, the same combined antibiotic therapy effectively reduced bacterial counts in an experimental rat model of chronic S. aureus osteomyelitis. Previous results indicated excellent penetration of both antibiotics into infected bone; 14, 15 however, since there was evidence of bacterial regrowth within the bones, it is likely that the treatment time of 21 days was insufficient to achieve bone sterilization. As bacterial regrowth occurred long after cessation of treatment, it appears that development of antibiotic resistance cannot account for treatment failure; previous use of this antibiotic combination in acute experimental osteomyelitis was not associated with emergence of drug resistance. 1 4 Although this antibiotic combination holds promise for the treatment of chronic osteomyelitis, the results indicate that longer treatment times are probably required than for acute osteomyelitis.
We have also demonstrated that chronic osteomyelitis is associated with persistent TNF induction within bone, in terms of both activity and TNF mRNA levels, which were not rapidly reduced by antibiotic therapy. As the bones were not sterilized, it is unclear what length of time would be required for bone histopathology and TNF activity and TNF mRNA levels to return to normal. This is similar to experimental endocarditis where dramatic reduction ( 5 log) in heart vegetation cfu by antibiotics was associated with only a 0.75-fold reduction of serum TNF levels. 23 Enduring elevated pro-inflammatory cytokine levels despite successful antibacterial therapy may be a characteristic of chronic infections.
TNF has been demonstrated to have a close involvement with the bone remodelling cycle. 24 Many cells within the bone microenvironment have been documented to release TNF, including macrophages, monocytes, mast cells and osteoblasts. [25] [26] [27] [28] Increased levels of TNF (and interleukin 1) have been implicated in the bone damage associated with chronic periodontal disease. 29 Inflammatory damage associated with sterile arthritis in mice 30 and rheumatoid arthritis in humans 31 can be reduced by immunotherapeutic intervention using an anti-TNF antibody. A TNF neutralizing antibody has also been successfully used to cure inflammation and bone loss in a rat model of talc-induced granulomatosis. 32 Several bacterial components that may be released during bacterial growth or antibiotic-induced lysis cause osteolysis 6 and are capable of inducing TNF, 12 resulting in an imbalance of normal bone physiology. 6 Pathological changes during staphylococcal osteomyelitis may be in part the result of surface-associated protein components of S. aureus acting directly to induce cells within bone to release several bone-resorbing factors including TNF, as well as acting independently of this cytokine to cause bone resorption. 13 The results of the present study suggest that accumulation of TNF in the bone microenvironment during experimental chronic osteomyelitis may at least in part be associated with the histopathological changes observed during this disease. Antibiotic therapy did not reduce elevated levels of bone TNF and did not rapidly reverse histopathology. It is tempting to speculate that bacterial components released during antibiotic lysis remain within the bone and act either directly or via TNF induction to prolong osteolysis and delay return to normal bone physiology. This would further suggest that appropriate adjunct therapy of osteomyelitis warrants future evaluation. For example, it may be interesting to investigate the effects of a combination of an anti-TNF neutralizing antibody together with antibiotic therapy on osteomyelitis, as neutralization of locally released TNF may inhibit persistent bone destruction despite successful bacteriological cure.
